CoChat

Effect of pegylated interferon‐α‐2a treatment on mental health during recent hepatitis C virus infection

Open access
Alavi, Maryam, Grebely, Jason, Matthews, Gail V, Petoumenos, Kathy, Yeung, Barbara, Day, Carolyn, Lloyd, Andrew R, Van Beek, Ingrid, Kaldor, John M, Hellard, Margaret, Dore, Gregory J, Haber, Paul S, the ATAHC Study Group · 2012 · Journal of Gastroenterology and Hepatology
Cited by 45

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background and Aim: Pegylated interferon (PEG‐IFN) treatment for hepatitis C virus (HCV) infection has neuropsychiatric side effects. Data on the effect of HCV treatment on mental health among injecting drug users (IDUs) are limited. We assessed mental health during treatment of recently acquired HCV, within a predominantly IDU population. Methods: Participants with HCV received PEG‐IFN‐α‐2a (180 µg/week) for 24 weeks; HCV/HIV received PEG‐IFN with ribavirin. Depression was assessed using the Mini‐International Neuropsychiatric Interview (MINI). Logistic regression was used to identify factors associated with depression at enrolment and during treatment. Also, the effect of depression prior to and during treatment on sustained virological response (SVR) was assessed. Results: Of 163 participants, 111 received treatment (HCV,n = 74; HCV/HIV,n = 37), with 76% ever reporting IDU. At enrolment, 16% had depression (n = 25). In adjusted analysis, depression at enrolment occurred less often in participants full‐/part‐time employed (adjusted odds ratio [AOR] 0.23; 95% confidence interval [CI]: 0.06, 0.82,P = 0.023) and more often in recent IDUs (AOR 3.04; 95% CI: 1.19, 7.72,P = 0.019). During treatment, 35% (n = 31) developed new‐onset depression. In adjusted analysis, poorer social functioning (higher score) was associated with new‐onset depression (score ≤ 9 vs score ≥ 17; OR 5.69; 95% CI: 1.61, 20.14,P = 0.007). SVR was similar among participants with and without depression at enrolment (60%vs 61%,P = 0.951) and in those with and without new‐onset depression (74%vs 63%,P = 0.293). Conclusions: Although depression at enrolment and during treatment was common among participants with recent HCV, neither influenced SVR. Participants with poor social functioning may be most at risk of developing depression during HCV therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1746.2011.07035.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 45

Metadata

Authors
Alavi, M., Grebely, J., Matthews, G. V., Petoumenos, K., Yeung, B., Day, C., Lloyd, A. R., Van Beek, I., Kaldor, J. M., Hellard, M., Dore, G. J., Haber, P. S., & the ATAHC Study Group
Venue
Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2012-04-20
Volume
27
Issue
5
Pages
957-965
ISSN
  • 0815-9319 (ISSN-L)
  • 1440-1746
OpenAlex
W1838542666
Cited by
45
References
3
FWCI
1.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of pegylated interferon‐α‐2a treatment on mental health during recent hepatitis C virus infection. https://app.cochat.ai/papers/10.1111/j.1440-1746.2011.07035.x
The paper
Alavi, M., Grebely, J., Matthews, G. V., Petoumenos, K., Yeung, B., Day, C., Lloyd, A. R., Van Beek, I., Kaldor, J. M., Hellard, M., Dore, G. J., Haber, P. S., & the ATAHC Study Group. (2012). Effect of pegylated interferon‐α‐2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.2011.07035.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.